Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

In this commentary, the authors discuss emerging evidence primarily from pharmacovigilance data and retrospective studies indicating a potential association between GLP-1 receptor agonists, like semaglutide and tirzepatide, and hair loss, although causality remains unproven, prompting recommendations for patient monitoring and further research.

This study found that among users of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide were associated with higher incidences of hair loss, particularly androgenetic alopecia and telogen effluvium, with rapid weight loss identified as a potential contributor to telogen effluvium.

This narrative review identifies telogen effluvium as a growing concern linked to weight-loss interventions, such as GLP-1 receptor agonists and bariatric surgery, attributing hair loss to systemic and metabolic stress rather than permanent hair follicle damage.